Treatment-resistant schizophrenia:Current insights on the pharmacogenomics of antipsychotics by Lally, John et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.2147/PGPM.S115741
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Lally, J., Gaughran, F., Timms, P., & Curran, S. R. (2016). Treatment-resistant schizophrenia: Current insights
on the pharmacogenomics of antipsychotics. Pharmacogenomics and Personalized Medicine, 9, 117-129.
10.2147/PGPM.S115741
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
© 2016 Lally et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Pharmacogenomics and Personalized Medicine 2016:9 117–129
Pharmacogenomics and Personalized Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
117
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PGPM.S115741
Treatment-resistant schizophrenia: current 
insights on the pharmacogenomics of 
antipsychotics
John Lally1–3
Fiona Gaughran1,3
Philip Timms4,5
Sarah R Curran5–7
1Department of Psychosis Studies, 
institute of Psychiatry, Psychology 
and Neuroscience, King’s College 
London, London, UK; 2Department of 
Psychiatry, Royal College of Surgeons 
in ireland, Beaumont Hospital, Dublin, 
ireland; 3National Psychosis Service, 
4START Team, South London and 
Maudsley NHS Foundation Trust, 
5King’s College London, 6South west 
London and St George’s Mental 
Health NHS Foundation Trust, 7St 
George’s University of London, 
London, UK
Abstract: Up to 30% of people with schizophrenia do not respond to two (or more) trials of 
dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS). 
Clozapine is still the only effective treatment for TRS, although it is underused in clinical prac-
tice. Initial use is delayed, it can be hard for patients to tolerate, and clinicians can be uncertain 
as to when to use it. What if, at the start of treatment, we could identify those patients likely to 
respond to clozapine – and those likely to suffer adverse effects? It is likely that clinicians would 
feel less inhibited about using it, allowing clozapine to be used earlier and more appropriately. 
Genetic testing holds out the tantalizing possibility of being able to do just this, and hence the 
vital importance of pharmacogenomic studies. These can potentially identify genetic markers 
for both tolerance of and vulnerability to clozapine. We aim to summarize progress so far, pos-
sible clinical applications, limitations to the evidence, and problems in applying these findings 
to the management of TRS. Pharmacogenomic studies of clozapine response and tolerability 
have produced conflicting results. These are due, at least in part, to significant differences in the 
patient groups studied. The use of clinical pharmacogenomic testing – to personalize clozapine 
treatment and identify patients at high risk of treatment failure or of adverse events – has moved 
closer over the last 20 years. However, to develop such testing that could be used clinically will 
require larger, multicenter, prospective studies.
Keywords: personalized medicine, pharmacogenetics, treatment resistant psychosis, clozapine, 
pharmacokinetic, pharmacodynamic
Introduction
Treatment-resistant schizophrenia (TRS) affects ~30% of people with a diagnosis of 
schizophrenia.1 TRS is defined as nonresponse to at least two trials of antipsychotic 
medication of adequate dose and duration,2 at which point, the antipsychotic clozapine 
is indicated. Interestingly, clozapine does not work better than other antipsychotics in 
first-episode cases.3 Recent work suggests that different underlying mechanisms are 
responsible for the symptoms in TRS.4 The changes in presynaptic dopamine transmis-
sion usually seen in schizophrenia are absent in TRS,5 but we do see changes in anterior 
cingulate glutamate activity.6 It is therefore not surprising that other antipsychotics, 
which all have their main effects on dopamine receptors, fail to work in people with 
TRS. This may come to be seen less as treatment resistance and more as a failure to 
direct treatment toward the relevant underlying problem.
Clozapine is unique as it is the only evidence-based treatment for TRS,2,7,8 with 
60%–70% of those treated showing a response.9 However, some patients with TRS 
do not respond to clozapine. At present, we can identify neither those who will 
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improve on clozapine nor those who will not respond to 
other antipsychotics.
Despite its unique efficacy in TRS, clozapine is under-
prescribed in most countries. Levels of use are far less than 
the ~50%–60% of TRS patients who could benefit from 
it.10–12 The evidence suggests that it is only used after a 
delay of several years.13 The reasons for this include a fear 
of side effects, and the inconvenience of therapeutic blood 
monitoring. This means that many who could benefit from 
clozapine do not.14,15 Moreover, when clozapine is not used 
in TRS, patients are often treated with nonevidence-based, 
high-toxicity, high-dose antipsychotic treatments, and 
polypharmacy.13 If clozapine does work, it can be trans-
formative, improving psychotic symptoms, function, and 
longevity. However, the process of establishing its efficacy 
(or otherwise) can be lengthy (up to a year) and grueling 
for the patient. This evaluation of efficacy and side effects is 
more difficult because there is really no alternative medica-
tion for TRS.
There are currently no evidence-based pharmacotherapies 
for the 30% of TRS patients who fail to respond to clozap-
ine9,16 or those who discontinue clozapine due to adverse 
events.17,18 As well as facilitating the use of clozapine, phar-
macogenomics and personalized medicine could support the 
development of new medications.
Personalized medicine and 
pharmacogenomics in TRS
Personalized, or precision medicine uses “genetic or other 
biomarker information to improve the safety, effectiveness, 
and health outcomes of patients via more efficiently targeted 
risk stratification, prevention, and tailored medication and 
treatment management approaches”.19
In TRS, by considering a person’s individual genomic, 
epigenetic, molecular, cellular, clinical, behavioral, and 
environmental characteristics, it should be possible to tailor 
appropriate preventative and therapeutic interventions to that 
individual. This would allow for the safer and timelier introduc-
tion of clozapine in patients where it is likely to be effective.
The potential benefits and function of pharmacogenomics 
in schizophrenia are listed in Table 1.
Terminology
Pharmacogenomics
Pharmacogenomics looks at how genes control drug phar-
macokinetics and pharmacodynamics.20 The term is often 
used interchangeably with the term pharmacogenetics. 
Pharmacogenetics usually refers to how a specific gene or a 
set of genes can influence a patient’s response to medicine(s).
Pharmacogenomics looks at how a person’s whole genetic 
makeup can influence his/her responses to medicine(s). Early 
studies focused on pharmacogenetic approaches, looking 
at groups of genes that seemed to be likely to be involved 
with a particular disorder – “candidate” genes. Now, with 
newer technologies, pharmacogenomic approaches are more 
common.
In this article, we use the term pharmacogenomics to 
refer to both approaches.
epigenetics
Epigenetics refers to the regulation of translation of DNA. 
This is mainly through changes in DNA methylation and 
chromatin structure, histone modification, RNA editing, 
and nontranscriptional gene silencing via micro-RNAs.21,22
Pharmacogenomics in TRS
Patients with TRS have an excess of rare disruptive variants 
both in gene targets of antipsychotics and in genes with 
evidence for a role in antipsychotic efficacy.23,24 A number 
of studies in TRS patients have looked at the effects of varia-
tions in the genes responsible for the effectiveness, adverse 
effects, and metabolism of clozapine.25–28 Newer genomic 
approaches using genome-wide association study (GWAS) 
and exome sequencing (to identify rare as well as common 
genetic variants across the genome) are set to facilitate a new 
era of pharmacogenomic testing as a guide to personalized 
treatments.29
Barriers to pharmacogenomic testing in TRS are outlined 
in Table 2, and the characteristics of TRS which attenuate 
some of these challenges are shown in Table 3.
Pharmacogenomics and clozapine 
response
One way to use pharmacogenomic testing in TRS would be 
to identify specific genetic variations that predict a good 
response to clozapine, or a low risk of adverse events. Pre-
scribing decisions could then be informed by the genetic 
test findings.
Table 1 Uses of tools provided by pharmacogenomic biomarkers 
in TRS
Avoid toxicity and subsequent ADRs
Avoid underdosing and subsequent lack of efficacy
Avoid drug use by hypersensitive individuals
improve clinical diagnosis
Rescue drugs previously withdrawn because of ADRs
Note: Reproduced with permission of Royal College of Psychiatrists via 
PLSClear, Lally J, MacCabe JH. Personalised approaches to pharmacotherapy for 
schizophrenia.117
Abbreviations: TRS, treatment-resistant schizophrenia; ADRs, adverse drug 
reactions.
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TRS and pharmacogenomics of antipsychotics
Two meta-analyses confirm the importance of the dopa-
minergic system,28,30 and one confirms the impact of the sero-
tonergic system for the antipsychotic effect of clozapine.25
Dopaminergic system
A dopamine receptor type 3 functional polymorphism, Ser-
9Gly, has been associated with clozapine efficacy in several 
studies.31,32 The direction of this association was further 
shown in a meta-analysis, although it was not found to be 
statistically significant.30 Genetic variants of the dopamine 
receptors type 2 and type 1 and dopamine transporter haplo-
types have also been found to be associated with clozapine 
efficacy.26,33 Overall, these findings suggest that the dopa-
minergic system plays some part in mediating clozapine 
response. However, a recent meta-analysis25 did not identify 
the previously reported association between dopamine 
genes DRD2 rs1799732 and DRD3 rs6280 and clozapine 
response.26,28 This study25 applied a stricter inclusion criteria 
than the previous meta-analysis,26 only including studies 
where clozapine was investigated alone (rather than with 
other antipsychotics).
Serotonergic system
Several serotonergic receptor type 2A (5-HT2A) gene poly-
morphisms have been associated with response to clozap-
ine,34 although these associations have not been universally 
replicated.27,35 Studies have demonstrated an association 
between clozapine efficacy and genetic variants in the sero-
tonin receptor type 2A (5-HT2A),34 type 2C (5-HT2C),36 
and type 6 (5-HT6)37 and serotonin transporter (5-HTT) 
genes,36 although these findings have not been consistently 
replicated.26–28 The most recent meta-analysis identified three 
genetic variants within serotonin genes associated with the 
response to clozapine: rs6313 and rs6314 within the 5-HTR2A 
gene and rs1062613 within the 5-HT3A gene.25
No single polymorphism is predictive of clozapine 
response. So, attempts have been made to combine poly-
morphisms in several genes to predict such a treatment 
response. A landmark study was conducted by Arranz et al, 
in which one test combined six different polymorphisms in 
neurotransmitter receptor-related genes (the included poly-
morphisms were 5-HT2A 102-T/C and His452Tyr, 5-HT2C 
330-GT/244-CT, and Cys23Ser, 5-HTTLPR, H2 1018-G/A). 
This resulted in a 77% success in the prediction of clozapine 
response (P=0.0001).36 This study was the first demonstration 
that pharmacogenomics could be used to personalize a psy-
chiatric treatment, and this test was subsequently marketed. 
However, this finding was not replicated,38 and the test was 
withdrawn from the market. However, there were differences 
in clinical characteristics in the replication sample from the 
sample in the original study. The replication sample had a 
shorter period of clozapine use compared to the original 
study, which assessed long-term clozapine treatment (mean 
duration >1 year).36 The shorter duration of clozapine use in 
the replication sample may have led to some being prema-
turely categorized as nonresponders,39 as clozapine response 
can take up to 12 months.9
Metabolism of clozapine – CYP1A2 
enzyme
Pharmacokinetic research in schizophrenia has largely 
focused on the cytochrome P450 (CYP) family. It was hoped 
that genotyping for CYP enzyme deficiencies could offer a 
relatively simple solution for optimizing dosing and pre-
dicting response to clozapine. However, this has not proved 
consistent in practice. The genes coding for these enzymes 
are highly polymorphic, and the effects of many of the 
genetic differences contribute to differential metabolism of 
psychotropic agents. Patient phenotypes can be grouped into 
three categories – poor metabolizers, extensive metaboliz-
ers (corresponding to normal CYP activity), and ultrarapid 
metabolizers.40
Therapeutic drug monitoring of plasma clozapine and 
of its major plasma metabolite N-desmethylclozapine 
Table 2 Challenges in using pharmacogenomics to predict 
clozapine effect in TRS
Characterizing/quantifying drug response
Measuring antipsychotic efficacy
Nonadherence
Treatment duration – early benefits with antipsychotic response vs 
longer duration of effect with clozapine
Concurrent medication use – mood stabilizers; crossover of 
antipsychotics during switching
Patient characteristics
Differential diagnosis and unclear diagnostic boundaries
Illness course – first-episode psychosis and TRS
Comorbidities – substance misuse; depression
Risk of neutropenia increased in those of African Caribbean ethnicity
Baseline characteristics: eg, lower BMi and greater risk of weight gain 
with clozapine treatment
Abbreviations: TRS, treatment-resistant schizophrenia; BMi, body mass index.
Table 3 Characteristics of TRS which make it a more useful 
population in which to conduct pharmacogenomic studies
increased uniformity in diagnosis
Ability to monitor adherence with plasma clozapine concentrations
Long-term follow-up of TRS patients within clinical services
The existence of registers for clozapine-monitoring services
Abbreviation: TRS, treatment-resistant schizophrenia.
 
Ph
ar
m
ac
og
en
om
ics
 a
nd
 P
er
so
na
liz
ed
 M
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
73
.1
26
.1
88
 o
n 
20
-D
ec
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Pharmacogenomics and Personalized Medicine 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
120
Lally et al
( norclozapine) in a predose sample can help to track adher-
ence, and to adjust dose to minimize toxicity. For therapeutic 
effectiveness, a minimum threshold plasma clozapine level 
has been identified at 0.35 mg/L.41–45 Monitoring plasma 
levels of clozapine can identify the following:
 • Patients who do not reach therapeutic plasma concentra-
tions at expected therapeutic doses
 • Those who have reached an adequate dose (giving 
plasma clozapine concentrations of 0.35–0.5 mg/L)
 • Those who need prophylactic treatment with antiepilep-
tic drugs to support a trial of a higher plasma clozapine 
concentration (>0.6 mg/L)
 • Partial responders who may benef it from drug 
augmentation
 • Those who have plasma toxicity
The CYP1A2 enzyme is primarily responsible for clo-
zapine metabolism. The genetic studies of clozapine drug 
response are supported by the identification of multiple 
functional variants in CYP1A244,45 with well-defined effects 
on clozapine metabolism. A number of studies have provided 
evidence to suggest that the CYP1A2*1F allele is associ-
ated with clozapine response,46–48 with the response being 
linked to plasma concentration levels in the study by Eap 
et al. Further studies have failed to identify an association 
between the CYP1A2 polymorphism and plasma clozapine 
concentrations, when controlling for clozapine dose and body 
weight.49 CYP1A2*1F polymorphisms were associated with 
a super-refractory schizophrenia group of patients, compared 
to controls, thus replicating previous work, and identifying 
this polymorphism as a moderator of clozapine response.50 
However, as is the case in clozapine pharmacodynamic 
pharmacogenetic research, other studies have not replicated 
these findings in relation to CYP1A2 polymorphism and 
clozapine response.51,52 Ethnic variation between the study 
populations has been suggested as a cause of this, with there 
being a higher frequency of the CYP1A2*1F allele in those 
of European ancestry.27
Individuals with increased activity of CYP1A2 enzymes 
are likely to have reduced levels of medication metabolized 
by that pathway. Case series have reported ultrarapid metabo-
lizers of clozapine presenting as resistant to treatment, and 
conversely with increased plasma clozapine concentrations 
occurring with the concurrent use of fluvoxamine, a CYP1A2 
inhibitor.53 There is substantial individual variability in 
plasma clozapine concentrations, with higher concentrations 
in men and lower concentrations in those who smoke.54 A 
mutation (CYP1A2*1F) in intron 1, which confers a high 
inducibility of CYP1A2 in smokers, is a suggested explana-
tion for this rapid CYP1A2 activity.55 However, pharmacoge-
netic testing for CYP1A2 variations in relation to clozapine 
metabolism remains at an early stage. Larger studies are 
needed in clozapine-treated TRS patients, which clearly 
identify concurrent inducers (such as smoking), in order to 
clarify the relationship between faulty CYP1A2 alleles and 
plasma clozapine concentrations.
The inconsistent findings in relation to CYP1A2 and 
clozapine response were highlighted in a recent systematic 
review, which identified only a single-nucleotide polymor-
phism (SNP) in ABCD1 (3435TT (rs1045642)) to be pre-
dictive of plasma clozapine concentrations and response to 
clozapine,56 but further longitudinal studies are required to 
clarify the role of ABCD1.
Pharmacogenomic testing has been done with warfarin-
dosing algorithms, where both genetic and nongenetic factors 
are used to tailor warfarin dosing.57 However, the translation 
of pharmacogenomic testing in predicting clozapine response 
has not, so far, been successful. Much of the research has 
focused on the CYP system, but at the moment, the use of 
CYP testing to guide the prescribing and dosing of clozapine 
cannot be justified.
Clozapine and the glutamate system
Even though clozapine is our only evidence-based treatment 
in TRS, we still do not understand how it works. This limits 
our ability to generate hypotheses as to which pharmacoge-
nomic tests might be relevant. It has been suggested that the 
glutamate system may mediate response to clozapine,58 and 
this had been investigated more recently.59 Both preclinical 
and human studies have suggested that clozapine augmenta-
tion of glutamatergic neurotransmission leads to reductions in 
central glutamate levels. This has been suggested as a possible 
mechanism mediating clozapine response.60–62
The role of glutamate in the pathogenesis of schizo-
phrenia is supported by recent findings from the Psychiatric 
Genomics Consortium and other studies. Genome-wide sig-
nificant associations with schizophrenia have been observed 
in glutamate system genes GRM3, GRIN2A, GRIA1, and 
GRIN2B.63,64 Neuroimaging studies have provided evidence 
that there are biological differences in glutamatergic neu-
rotransmission between treatment-resistant and treatment-
responsive schizophrenia.5,6 TRS patients have demonstrated 
higher glutamate levels in the anterior cingulate cortex,6 with 
relatively normal dopamine functioning, in comparison to 
treatment-responsive patients.5 These observations indicate 
that the persistence of symptoms in TRS may be associated 
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with elevated anterior cingulate glutamate levels. In TRS, a 
handful of studies have investigated glutamate system genes 
in relation to clozapine response. These have largely focused 
on variants in GRIN2B, which codes for the 2B subunit of 
the glutamate N-methyl-d-aspartate receptor.65 Further work 
is needed to clarify any potential role for the glutamate sys-
tem in the pathophysiology of TRS and clozapine response. 
We need to investigate a wider variety of glutamate genetic 
variants, using prospective study samples, to link the genetic 
findings to neuroimaging, and phenotypic characteristics, 
including plasma clozapine concentrations.
Pharmacogenomics and clozapine 
adverse events
Clozapine and agranulocytosis
One of the main reasons for the underuse of clozapine is 
patient and clinician fears about sudden clozapine-induced 
agranulocytosis (CIA).66 This occurs with an incidence 
of 0.8% at 1 year after starting clozapine treatment.67 The 
highest incidence is at 6–18 weeks.68 The mechanism of this 
idiosyncratic event is unclear, though it is certainly multi-
factorial, with some evidence for genetic variance increasing 
the susceptibility to CIA.69
The best genetic evidence is for dysfunction in the 
human leukocyte antigen (HLA) system, composed of genes 
that are important in immune system modulation. A recent 
GWAS and exome-sequencing analysis reported significant 
associations between genetic variants in HLA and CIA. 
This included genetic variants involved in the HLA-DQB1 
locus (a single amino acid at HLA-DQB1 (126Q) and an 
amino acid change in the extracellular binding pocket of 
HLA-B(158T)).69 A case–control study found that the odds of 
developing CIA were 16.9 times higher in patients carrying 
a cytosine instead of the usual guanine DQB1 genotype.70 
This SNP was incorporated into a commercially available 
test, with a sensitivity of 21.5% and a specificity of 98.4% for 
detecting the haplotype, indicating a 5.1% risk of developing 
agranulocytosis if the haplotype is present.70 Although the 
HLA-DQB1 locus may be implicated in CIA development, 
for the test to be clinically useful, it requires high sensitiv-
ity and specificity, and thus, the low sensitivity of the test 
has limited its use in clinical settings.71 This test gives a 1% 
(0.05×0.22) chance of identifying patients at risk of devel-
oping CIA, which is not very different from the risk for all 
patients treated with clozapine (0.8%).71,72
So far, a dose-dependent link between plasma clozapine 
concentrations and the risk of neutropenia and agranulocy-
tosis has not been consistently demonstrated.73,74 However, a 
recent GWAS meta-analysis identified a novel genome-wide 
significant association with clozapine-associated neutropenia 
and rs149104283, intronic to transcripts of SLCO1B3 and 
SLCO1B7, members of a family of hepatic transporter genes 
involved in drug uptake.75 This study75 offers a tantalizing 
suggestion that CIA may be related to plasma concentrations 
while offering a novel link between clozapine pharmacokinet-
ics and bioavailability and the genetic risk of neutropenia/
agranulocytosis.
The replication of an association between CIA and genetic 
variants involved in the HLA-DQB1 locus69,76–78 is promising, 
but the majority of those who develop a CIA are not carriers 
of the risk alleles. So, none of these pharmacogenomic tests 
are yet clinically useful.72
Clozapine and metabolic disturbance – 
candidate gene studies
Schizophrenia is associated with increased rates of cardio-
vascular morbidity79–82 and associated excess premature 
death, which translates to a 15- to 20-year shortened life 
expectancy for those with schizophrenia.83,84 There is an 
increased prevalence of weight gain, dyslipidemia, and type 
2 diabetes seen with both clozapine and olanzapine.80,85 Clo-
zapine is especially associated with weight gain, which can 
occur early in the course of treatment, before plateauing as 
the treatment continues.86–88
For clozapine-associated weight gain, the only consistently 
replicated genetic variant is the 759T/C polymorphism in the 
promoter region of the HTR2C gene (rs3813929).89–91 Those 
clozapine patients homozygous for the HTR2C gene 759C 
polymorphism have been shown to have increased obesity 
rates at 6 months of clozapine treatment.92 Conversely, those 
with the T allele for this polymorphism have shown less 
weight gain over the course of the first 6 months of clozapine 
treatment.93,94 However, as is typical of candidate gene stud-
ies, these results have not been consistently replicated, with 
frequent findings of no associations between the –759C/T 
polymorphism of the HTR2C gene and clozapine-associated 
weight gain and obesity.95–97 Further, in a recent review, a meta-
analysis could not be performed on genes associated with 
weight gain due to a lack of genetic data from studies in which 
clozapine was analyzed separately to other antipsychotics.25
Other candidate genes identified to be associated with 
clozapine-induced weight gain include LG,98–100 TNFα,101 
CNR1,102 ADRA
2A
,103,104 MC4R,105,106 and BDNF genes.107
Metabolic syndrome associated with clozapine use has been 
associated with polymorphisms in HTR2C,108–111 LG (G allele 
of the –2548A/G LG promoter polymorphism),100 the INSIG2 
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(INSIG2 rs11123469 C allele), which encodes a protein which 
mediates feedback control of lipid metabolism, with the C 
allele significantly overrepresented in those with metabolic syn-
drome,112 and MTHFR genes (MTTP rs1800591 T allele).113,114
An increased risk of dyslipidemia secondary to clozapine 
use is associated with a polymorphism in the PRKAR2B 
gene, detected in a GWAS of participants from the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) 
study.115 ApoC3 (TG haplotype) and ApoA5 (CG haplotype) 
genes were associated with decreased serum triglyceride and 
serum cholesterol levels, respectively, in clozapine-treated 
patients. The ApoC3 CC haplotype was associated with 
increased serum triglyceride levels.116
Table 4 summarizes significant findings from can-
didate gene studies of clozapine efficacy and side effe
cts.32–37,92–94,96,100,106,108,109,117–136
Epigenetics
Studies of genetic associations with schizophrenia are char-
acterized by nonreplication and significant heterogeneity. The 
heterogeneous course of schizophrenia makes it difficult to 
apply traditional gene–environment-based approaches137 and 
has led to speculation that epigenetic factors may mediate 
susceptibility and account for the “missing heritability”.138,139 
Epigenetic influences on disease phenotypes may explain the 
effect of early life stressors on risk of psychosis in later life.
epigenetics and antipsychotic use/
development
The dynamic nature of the epigenome means that, unlike 
pathogenic DNA sequence mutations, epigenetic disruption 
is potentially reversible, and thus a realistic target for phar-
macological intervention. Methylation of a promoter CpG 
island located ~30 kb upstream of the gene encoding MEK1 
was significantly correlated with lifetime antipsychotic use 
in postmortem frontal cortex brain samples.140 Epigenetic 
changes on GABAergic and glutamatergic gene promoters 
have been suggested as explanations for the therapeutic action 
of clozapine.141–143 This occurs at least in part due to increased 
GABAergic activity mediated by histone methylation and 
Table 4 Positive and negative candidate gene studies of clozapine treatment response and clozapine-induced metabolic disturbance 
in schizophrenia
Gene Variant Reported association Nonsignificant associations 
(references)
Dopamine
DAT Multiple33 improved psychotic symptoms 121
D1 Multiple118,119 improved psychotic symptoms –
D2 Taq A/B120 improved psychotic symptoms 35,122
D3 Ser9Gly32 Increased efficacy in those with  
Ser allele
36,123
Serotonin
5-HT2A 102 T/C34 C/C genotype: with improved  
response
124,127
–1438 G/A35 G/G genotype poorer response 128 (group treated with 
clozapine, amisulpride, 
olanzapine, or risperidone)
His 452Tyr124,125 Tyr associated with nonresponse 127,129
5-HT2C Cys23Ser126 Ser associated with increased 
efficacy
124,130
5-HT6 267 T/C37 improved response in T/T 
genotype
131
5-HT2C 759C/T92–94 C allele associated with weight gain 
and T allele with a protective effect
96
5-HT2C Cys23Ser-polymorphisms rs518147, rs1414334,  
and 5-HTR2C:c.1-142948(GT)n
108,109
increased risk of metabolic  
syndrome
LEP –2548A/G (GG/GA genotype)100 increased weight gain and risk of 
metabolic syndrome
132
MC4R rs17782313 C allele (CC genotype) increased weight gain 134
rs8087522 A allele106,133
D2 rs4436578 C allele135 increased weight gain
TNFa 308 G>A polymorphism TNFa gene (–308 GG 
genotype)101
increased weight gain 136
Notes: Although numerous studies suggest that clozapine-induced side effects and efficacy are associated with candidate gene polymorphisms, most findings are of modest 
effect, with inconsistent results to date (ie, multiple negative studies of candidate genes exist). Reproduced with permission of Royal College of Psychiatrists via PLSClear, 
Lally J, MacCabe JH. Personalised approaches to pharmacotherapy for schizophrenia.117
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chromatin relaxation, and the targeting of DNA demethyl-
ation via GADD45b.142 Clozapine, but not haloperidol, is 
associated with the induction of nuclear H3K9 acetylation144 
and an increase of GADD45b mRNA in mice.142 Epigenetic 
research into therapeutic mechanisms of clozapine action 
remains in its infancy, though findings to date suggest the 
possibility of future tests to predict clozapine responders and 
of novel therapeutic interventions.
Challenges in applying 
pharmacogenomics in TRS and 
future directions
Several factors contribute to the difficulty in implementing 
pharmacogenomic testing to predict clozapine tolerability 
and efficacy. Schizophrenia is a heterogeneous disorder, 
characterized by variability in clinical presentation, which 
makes it a challenging phenotype to accurately assess. While 
TRS may represent a distinct and more uniform subtype of 
schizophrenia,145 it is likely that remaining heterogeneity con-
tinues to obscure true genetic signals. Varying environmental 
and clinical factors impacting on clozapine response and 
tolerability further complicate pharmacogenomic research.
Some potential clinical risk factors for TRS have been 
suggested, such as a young age of illness onset (and spe-
cifically onset before the age of 20146), an insidious onset, a 
greater severity of negative symptoms at illness onset, living 
in less urban environments, comorbid personality disorders, 
and cumulative effects of lifetime trauma and adversity.146–153 
However, to date, the predictive value of demographic and 
clinical risk factors for TRS, linked to pharmacogenomic 
findings, has not been widely investigated. One recent study 
identified an association between treatment resistance and 
polygenic risk score, an association which was stronger in 
those with a younger age of illness onset and with poorer 
premorbid functioning.149 A more recent study, comparable 
in size, failed to identify an association between treatment 
resistance and polygenic risk score.153 Given these equivo-
cal findings, the use of common genetic variants to index a 
polygenic risk score to predict treatment resistance requires 
further evaluation using larger case–control population 
samples, and factoring in other clinical and demographic 
risk factors. This approach could clarify the utility of the 
polygenic risk score in predicting TRS.
Previous attempts to identify clinical predictors of clo-
zapine response have generally identified few predictors. The 
most consistently identified predictors of clozapine response 
include a later age of illness onset,154–156 more severe positive 
symptoms,154,157,158 an earlier use of clozapine in the illness 
course when treatment resistance emerges,159 and related to 
this, a lower number of antipsychotic trials and hospitaliza-
tions prior to clozapine use.160 As demonstrated in this review, 
candidate gene and genome sequence studies alone have 
not proved successful in identifying consistent predictors of 
clozapine response. Future pharmacogenomic studies could 
benefit from incorporating clinical risk factors for clozapine 
response, to guide the development of valid and useful clo-
zapine treatment algorithms for predicting response.
Pharmacogenomic studies of clozapine have also been 
limited by sample size. This is further compounded by the 
heterogeneity of participants, few measures of clozapine 
adherence, levels of concurrent medications, lack of con-
trolling for confounding factors such as smoking, and the 
absence of an agreed response to clozapine by a numerical 
reduction in scale scores (such as the Positive and Negative 
Syndrome Scale or the Brief Psychiatric Rating Scale score).
Probably as a result of such limitations, most positive 
candidate gene studies have not provided sufficiently robust 
findings nor been replicated. Meta-analysis has confirmed 
the need for replication studies of much larger sample sizes 
to detect real associations.25,27 Most pharmacogenomic 
studies in clozapine use have focused on candidate genes 
coding for specific enzymes believed to be involved in the 
absorption, distribution, metabolism, and/or excretion of 
antipsychotic medications.27,28,89 Studies using the candi-
date gene approach are inherently limited by the genes 
chosen, while linkage method studies require families and 
are impractical for most pharmacogenomic questions. The 
introduction of GWAS has opened the doors to genetic 
research which transcends candidate gene studies.63,69,149,161 
GWAS research has developed rapidly, and there is a grow-
ing set of GWASs related to phenotypes, including TRS.145 
However, this remains a novel area, and there are but a 
handful of studies assessing clozapine response using a 
polygenic risk-scoring method (based on GWAS).24,161,162 
GWAS has been more widely applied in the identification 
of genetic variants associated with clozapine adverse events, 
such as agranulocytosis69 and metabolic disturbance. In the 
most noteworthy GWAS of clozapine metabolic effects from 
the CATIE study, positive associations for metabolic dis-
turbance (SNP in PRKAR2B gene)115 were identified, while 
in other GWASs, associations with the MC4R gene and 
weight gain with clozapine use were seen.106,163 However, 
the concurrent use of multiple antipsychotics and the failure 
to consider clozapine separately preclude meta-analysis of 
the genetic variants contributing to clozapine metabolic 
disturbances.27
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Future directions
Barriers to implementation of pharmacogenomic 
testing in TRS
The translation of pharmacogenomic research findings into 
clinical practice has been slow in all medical settings.164,165 
In psychiatry, the limitations of the available tests have pre-
vented the use of pharmacogenomic testing in the clinical 
use of clozapine and other antipsychotics. The reasons for 
this include the limitations of the candidate gene approach 
and study heterogeneity.
Substantial economic barriers also remain.166 The strati-
fication of patients with psychotic illness into more refined 
subsets may advance medication development, but it may 
also reduce the size of the potential market and deter industry 
investment.167 Drugs developed in this way may take longer 
to recoup development expenses. It may also prove less 
economic to develop drugs to treat rarer genetic subtypes 
of TRS or genetically determined TRS subtypes which are 
more prevalent in lower income countries.118
On the other hand, as technology advances, genotyping 
should become cheaper. In the future, the focus will shift from 
genotyping costs to the interpretation and production of reports 
for clinical use. The clear communication of pharmacogenomic 
test results will be a critical part of their effective clinical use.
Pharmacogenomic test results for the individual patient 
should be available for that patient’s lifetime. However, due 
to the fragmentation of health care services, this genetic test 
information may be lost as the patient moves from one health 
care setting to another. This could be overcome by using 
integrated patient records. Currently, in the UK, pharmacoge-
nomic information might sit best in primary care records, 
ensuring that it is available for all potential prescribers.
Furthermore, clinicians are not used to using this kind of 
information to inform their prescribing. This is, perhaps, not 
surprising when these tests have limited clinical usefulness.168 
For example, in schizophrenia in general, the characterization 
of CYP genes has not led to the widespread utilization of 
these tests to predict response and side effects to treatment.169 
Surveys have indicated that when clinicians have used phar-
macogenomic tests, they have focused on the assessment of 
medication intolerance rather than response.170
Overcoming barriers
Even when pharmacogenomic tests become more clinically 
informative, it will still be necessary to ensure that clini-
cians are fully informed of the ways in which such tests can 
improve clinical practice. Health service providers will need 
to be convinced that this technology is cost effective and that 
it represents an improvement over the current trial-and-error 
approaches to prescribing. Thorough implementation will 
require clinician education, the incorporation of pharma-
cogenomic testing advice into clinical guidelines for TRS, 
and integrated medical records.171
Conclusion
Personalized medicine in the diagnosis and treatment of TRS 
will involve multiple strands including genetics, neuroimaging, 
and biomarkers. The use of genomic markers should enable us 
to create more identifiable homogenous subgroups of schizo-
phrenia patients. In turn, this should mean that we can better 
identify both those who will respond to clozapine and those 
who will better tolerate it. Such predictive testing should allow 
low-risk patients to get the most benefit from clozapine while 
reducing the risk of adverse events for higher risk patients.
However, given the weakness of the tests currently avail-
able, pharmacogenomic testing is not yet at a point where it can 
effectively inform the clinical use of clozapine. What needs to be 
done? We need clearly agreed definitions of TRS and standard-
ized measurements of response to treatment. This would allow 
the construction of large and well-characterized samples which 
could be subject to prospective assessments. Such studies will 
need to link genetic data with phenotypic stratification. They 
will also need to allow for the effects of other factors such as 
current and historical use of medication, doses and plasma con-
centrations of clozapine, and lifestyle factors such as smoking.
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